NeuSpera Medical Inc.

Based in the US, NeuSpera Medical Inc. specializes in developing innovative medical technologies aimed at improving treatment for urinary incontinence, particularly through their advanced neuromodulation systems. NeuSpera Medical Inc. , founded in 2013 in San Jose, US, focuses on developing neuromodulation systems.

The company recently secured USD 23 mn in Series D funding on July 15, 2024, led by Vertex Ventures HC and Treo Ventures, with participation from Olympus Innovation Ventures. Alexander Yeh is the founder, and Milton Morris serves as CEO. NeuSpera Medical primarily offers the Neuspera Implantable Sacral Neuromodulation (SNM) System, targeting Urinary Urgency Incontinence (UUI), a symptom of Overactive Bladder (OAB). This system features a minimally invasive implant and a wearable device for effective nerve stimulation, enhancing bladder control.

The product is mainly marketed in the United States to healthcare professionals and patients seeking better management of UUI. NeuSpera Medical's revenue model is based on the distribution of their implantable SNM System through healthcare providers and medical institutions. The company emphasizes direct sales to hospitals and clinics, aiming to establish partnerships that facilitate access to their technology and support clinical investigations. While specific pricing details for the Neuspera SNM System are not disclosed, the model focuses on direct relationships with healthcare providers to enhance patient outcomes.

In July 2024, NeuSpera Medical raised USD 23 mn in Series D funding to support the FDA premarket approval of their ultra-miniaturized Neuspera System, designed to address urinary urge incontinence (UUI). The company plans to leverage this funding to enhance product development and expand market reach as they aim to introduce new products in the coming years.